Kent Chak-yu So MBChB , Jonathan Yap MD , Guang-yuan Song MD , Karl Poon MBBS , Shih-Hsien Sung MD , Mann Chandavimol MD , Kentaro Hayashida MD , Duk-Woo Park MD , See-Hooi Ewe MD , Mi Chen MD , Vyanne Hei-tung Chan MBBS , Juri Iwata MD , Tarinee Tangcharoen MD , Paul Tern MD , Han-Su Park MD , Mirvat Alasnag MD , Yohei Ohno MD , Jimmy Kim Fatt Hon MD , Rohan Bhagwandeen MD , Minoru Tabata MD, PhD, MPH , Yat-yin Lam MD
{"title":"Epidemiology of Valvular Heart Disease in Asia Pacific Region","authors":"Kent Chak-yu So MBChB , Jonathan Yap MD , Guang-yuan Song MD , Karl Poon MBBS , Shih-Hsien Sung MD , Mann Chandavimol MD , Kentaro Hayashida MD , Duk-Woo Park MD , See-Hooi Ewe MD , Mi Chen MD , Vyanne Hei-tung Chan MBBS , Juri Iwata MD , Tarinee Tangcharoen MD , Paul Tern MD , Han-Su Park MD , Mirvat Alasnag MD , Yohei Ohno MD , Jimmy Kim Fatt Hon MD , Rohan Bhagwandeen MD , Minoru Tabata MD, PhD, MPH , Yat-yin Lam MD","doi":"10.1016/j.jacasi.2025.03.011","DOIUrl":null,"url":null,"abstract":"<div><div>Valvular heart disease poses a significant health burden in the Asia-Pacific region, with its epidemiology varying widely across countries caused by diverse socioeconomic and health care situations. Rheumatic heart disease remains prevalent, especially in low- to middle-income areas, while degenerative valvular diseases are emerging in developed regions caused by an aging population. Significant disparities in access to health care and intervention result in variable clinical outcomes. In the past decade, transcatheter interventions have revolutionized the management of patients with valvular heart disease globally. In the Asia-Pacific region, the uptake and development of transcatheter valvular interventions has been slow until recent years. Continued collaboration across the Asia-Pacific region is essential to mitigate the impact of the upcoming surge of valvular heart disease in this diverse and rapidly changing area.</div></div>","PeriodicalId":73529,"journal":{"name":"JACC. Asia","volume":"5 6","pages":"Pages 718-743"},"PeriodicalIF":0.0000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JACC. Asia","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2772374725002248","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Valvular heart disease poses a significant health burden in the Asia-Pacific region, with its epidemiology varying widely across countries caused by diverse socioeconomic and health care situations. Rheumatic heart disease remains prevalent, especially in low- to middle-income areas, while degenerative valvular diseases are emerging in developed regions caused by an aging population. Significant disparities in access to health care and intervention result in variable clinical outcomes. In the past decade, transcatheter interventions have revolutionized the management of patients with valvular heart disease globally. In the Asia-Pacific region, the uptake and development of transcatheter valvular interventions has been slow until recent years. Continued collaboration across the Asia-Pacific region is essential to mitigate the impact of the upcoming surge of valvular heart disease in this diverse and rapidly changing area.